DUBLIN--(BUSINESS WIRE)--The "Global Generic Drug Litigation Updates on the Latest Para IV Events" report has been added to ResearchAndMarkets.com's offering.
This report is published every month covering important updates on Para IV litigations. The analyses gets updated every time when an important development as regards the product Para IV litigation happens. In other words, it is not only comprehensive but also updated.
Para IV litigations remains the main stay for any generic company focused on the US generics market and consequently account for the largest chunk of revenues for all the major pharma companies in India. Para IV Winners and Losers is an analyses of major developments in the space in a particular month.
In month of June 2019, although the total settlements/outcomes declined month on month marginally, it marginally increased as % of overall developments for the month. 11 out of the 20 developments this month relate to settlements/outcomes vs 12 out of 26 in the month of May 2019.
No. of Para IV filings (ex-FTFs) decreased, No. of Para IV filing (incl FTFs) also decreased in this month. 7 out of the 20 developments this month relate to Para IV (ex FTFs) No. of Para IV filings on complex generics (non-oral solids) almost remains same in last four months. 5 out of the 9 Para IV filed this month are on Compex generic drugs.
Interesting developments this month:
- Some of the notable developments were related to Naproxen sodium, Nascobal and Kybella. Low competition opportunity emerges in Invokamet, Invokana and Vimovo for some companies.
- Other company specific development includes Para IV filing (incl FTFs) and subsequent litigation in Bryhali and Injectafer. Para IV filing (ex FTFs) and following litigation on Afinitor, Inlyta and Banzel (Oral Suspension) were also observed.
- Finally, increasing competition is seen in products like Xarelto, Prolensa, Lexiscan, Glumetza.
Companies covered in previous issues include:
- Bion pharma Lupin
- Dr Reddy's
- Fresenius Kabi
- MSN Labs
- Teva Actavis
- Zydus Cadila
For more information about this report visit https://www.researchandmarkets.com/r/5m12e9